BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Yaghoubi Naei V, Monkman J, Sadeghirad H, et al. (2024) Spatial proteomic profiling of tumor and stromal compartments in non-small-cell lung cancer identifies signatures associated with overall survival. Clinical & Translational Immunology. 13: e1522 |
Yaghoubi Naei V, Ivanova E, Mullally W, et al. (2024) Characterisation of circulating tumor-associated and immune cells in patients with advanced-stage non-small cell lung cancer. Clinical & Translational Immunology. 13: e1516 |
Ahmed M, Wuethrich A, Constantin N, et al. (2023) Liquid Biopsy Snapshots of Key Phosphoproteomic Pathways in Lung Cancer Patients for Diagnosis and Therapy Monitoring. Analytical Chemistry |
Paz-Ares LG, Ciuleanu T, Pluzanski A, et al. (2022) Safety of First-line Nivolumab Plus Ipilimumab in Patients With Metastatic Non-Small Cell Lung Cancer: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer |
Sadeghi Rad H, Bahrami T, Layeghi SM, et al. (2022) Immunotherapeutic targets in non-small cell lung cancer. Immunology |
Shiravand Y, Khodadadi F, Kashani SMA, et al. (2022) Immune Checkpoint Inhibitors in Cancer Therapy. Current Oncology (Toronto, Ont.). 29: 3044-3060 |
Brims FJ, McWilliams A, Harden SV, et al. (2022) Lung cancer: progress with prognosis and the changing state of play. The Medical Journal of Australia. 216: 334-336 |
Herath S, Sadeghi Rad H, Radfar P, et al. (2022) The Role of Circulating Biomarkers in Lung Cancer. Frontiers in Oncology. 11: 801269 |
Malapelle U, Pisapia P, Addeo A, et al. (2021) Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer. Expert Review of Molecular Diagnostics. 1-14 |
Kulasinghe A, O'Leary C, Monkman J, et al. (2021) The identification of circulating tumour DNA using MassARRAY technology in non-small-cell lung cancer (NSCLC). Lung Cancer (Amsterdam, Netherlands). 160: 73-77 |